During Thursday’s Current trade, Shares of Barclays PLC (ADR) (NYSE:BCS), lost -0.73% to $15.00.
Weak global growth, driven by weakness in emerging markets, especially in China, drove the Q3 market selloff, according to Barclays’ latest flagship quarterly research publication Global Outlook: Position for mediocre growth. With China deceleration unlikely to reverse any time soon, and developed market growth predictable to remain steady but not spectacular, investors should tilt their equities exposure toward a more neutral position, from the modest overweight position recommended in the last Global Outlook.
While the growth of advanced economies has been subpar by historical standards, the global consumer has been a source of strength in the US, Europe and Japan, with consumption assisted by tightening labor markets and weak inflation. Tighter labor markets in the US, the UK and Japan mean that central banks may be more cautious about further monetary policy accommodation, despite a subdued inflationary outlook driven by softer demand and excess capacity in China and continental Europe. Government bonds appear less attractive as a ‘safe haven’ than during earlier stages of the recovery.
Barclays PLC, through its auxiliaries, provides various financial products and services worldwide. It offers personal and corporate banking, mortgage, and wealth and investment administration services to individuals and businesses; consumer payments products and services to consumers and merchants; and retail and business banking, corporate and investment banking, and wealth administration and insurance services.
Shares of Nordic American Tanker Ltd (NYSE:NAT), declined -1.40% to $15.52, during its current trading session.
Nordic American Tankers Limited (“NAT” or “the Company”) declared that it had reached a contract to acquire two 2010 built ships for delivery to NAT in September and October 2015. The first of these vessels was taken over recently and has been renamed “Nordic Light”.
The delivery of its sister ship is predictable to take place during October. Thereafter, the Company will have a fleet of 26 Suezmax vessels counting two newbuildings to be delivered in August 2016 and in early 2017.
Going forward, NAT is seeking to enhance its dividend and earnings capacity through further expansion when the time is right to do so. We believe that our strong balance sheet and our well defined and transparent operating model, counting quarterly dividend payments, give the Company a strong competitive position.
Nordic American Tankers Limited, a tanker company, engages in acquiring and chartering double-hull tankers. As of December 31, 2014, it owned 24 Suezmax crude oil tankers, counting two new buildings under construction.
Concert Pharmaceuticals Inc (NASDAQ:CNCE), during its Thursday’s current trading session decreased -5.12% to $21.31.
Concert Pharmaceuticals, Inc. (CNCE) declared positive data from a Phase 1 single ascending dose clinical trial of CTP-656. CTP-656 is a novel deuterium-modified version of ivacaftor, which is commercially accessible as a single agent under the name Kalydeco® and as part of a fixed-dose combination therapy called Orkambi®. The clinical results continue to support the development of CTP-656 as a once daily potentiator for the treatment of certain cystic fibrosis genotypes as monotherapy or in combination with other CFTR modulators. CTP-656 demonstrated a superior pharmacokinetic profile contrast to Kalydeco, current standard of care. Results of the Phase 1 trial also showed that CTP-656 was well-tolerated and its safety profile was comparable to Kalydeco. The Phase 1 single dose results were presented during the “hot off the press” session at the Cystic Fibrosis Trusts UK Conference 2015 in Manchester, England.
“CTP-656 is a new chemical entity that we designed to provide superior pharmacokinetic properties while leveraging the known safety and efficacy of Kalydeco. Based on data from our initial clinical evaluation, we are extremely happy with the compound’s profile,” stated James V. Cassella, Ph.D., Chief Development Officer at Concert.
Concert Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, discovers and develops small molecule drugs for central nervous system disorders, genetic diseases, renal disease, inflammatory disease, and cancer.
Finally, Amicus Therapeutics, Inc. (NASDAQ:FOLD), decreased -4.79%, to $14.49.
Amicus Therapeutics (FOLD), a biotechnology company at the forefront of rare and orphan diseases, recently declared that John F. Crowley, Chairman and Chief Executive Officer, will present a corporate overview at the LEERINK Partners 4th Annual Rare Disease Roundtable in New York, NY on Wednesday, September 30, 2015 at 2:45 p.m. ET.
Amicus Therapeutics, Inc., a biopharmaceutical company, develops and commercializes therapeutic products for rare and orphan diseases. Its product candidate is a small molecule that can be used as a monotherapy and in combination with enzyme replacement therapy (ERT) for Fabry disease.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should/might occur.
